French study to reveal true COVID-19 infection rates during lockdown easing
NCT ID NCT04429594
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is following 1,000 people in the Alpes-Maritimes region of France to see how many were infected with the coronavirus during the deconfinement period. Researchers are using blood tests to measure immune responses and will also look at how air pollution might affect the immune system. The goal is to better understand the spread of the virus and its impact on health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide a clearer picture of how many people were infected with COVID-19 and how their immune systems responded, helping guide public health decisions.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may be influenced by factors like seasonality or changes in behavior.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2020
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Any major subject, voluntary, exposed to the public from 11 May 2020 informed of the study by partner institutions (Departmental Council 06), affiliated to a social security scheme, Exclusion Criteria: * Subject protected by law under tutorship or guardianship, or who cannot participate in a clinical study under the terms of Article L. 1121-16 of the French Public Health Code
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronavirus infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Nice Hospital
RECRUITINGNice, 06000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an old malaria drug help fight severe COVID-19?
- New vaccine aims to shield against multiple coronaviruses at once
- Massive COVID-19 biobank aims to unlock secrets of severe disease
- Real-World data on CPAP for COVID-19 respiratory failure
- Could a simple gas shield healthcare workers from COVID-19?
- Could a simple gas stop COVID-19 from getting worse?